Valion Bio, Inc. Common Stock (NASDAQ:VBIO) Stock Price Down 1.1% – Should You Sell?

Valion Bio, Inc. Common Stock (NASDAQ:VBIO)’s stock price dropped 1.1% during trading on Monday . The company traded as low as $0.47 and last traded at $0.5139. Approximately 180,809 shares traded hands during trading, a decline of 59% from the average daily volume of 437,637 shares. The stock had previously closed at $0.5195.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Valion Bio, Inc. Common Stock in a research note on Monday, April 20th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has an average rating of “Sell”.

Valion Bio, Inc. Common Stock Price Performance

The company’s 50-day simple moving average is $0.88 and its 200 day simple moving average is $1.10. The company has a market cap of $1.73 million, a PE ratio of -0.08 and a beta of 1.79. The company has a debt-to-equity ratio of 0.62, a quick ratio of 3.02 and a current ratio of 3.31.

Valion Bio, Inc. Common Stock (NASDAQ:VBIO) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($2.23) earnings per share (EPS) for the quarter.

About Valion Bio, Inc. Common Stock

Tivic Health Systems is a commercial-stage medical technology company that develops and markets non-drug, neuromodulation-based therapies for nasal and sinus health. The company’s solutions are designed to alleviate sinus pain, pressure and congestion through gentle microcurrent and vibration stimulation. By targeting the underlying nerve pathways in the nasal passages, Tivic Health aims to provide an alternative to over-the-counter and prescription medications without introducing systemic side effects.

The flagship product, ClearUP™ Sinus Pain Relief, is an FDA-cleared, hand-held device intended for home use.